TGN 167

Drug Profile

TGN 167

Alternative Names: TGN-167

Latest Information Update: 15 Apr 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Trigen Holdings AG
  • Class Anticoagulants; Antithrombotics
  • Mechanism of Action Thrombin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Thrombosis

Most Recent Events

  • 21 Feb 2008 No development reported - Phase-I for Thrombosis in United Kingdom (PO)
  • 31 May 2005 ProCorde GmbH has merged with Trigen Holdings plc to form Trigen Holdings AG
  • 24 Nov 2004 Trigen and Eurand have entered into an agreement to co-develop controlled-release formulations of TGN 167
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top